The pharmacology of bradykinin (BK)-related peptides, the kinins, has come a long way in recent decades, with the pharmacologic and then the molecular definition of 2 G protein-coupled receptors (GPCRs) that mediate their cellular actions, the B 1 and B 2 receptors (B 1 R, B 2 R). 1 Additional modern research tools include mouse strains in which one or both of the genes coding for kinin receptors have been deleted ("gene knockout" models). 2 The formation of kinins and their degradation by interesting peptidases, such as angiotensin-converting enzyme, will not be covered in the present text. The arduous nature of the analytic biochemistry of BK-related peptides is outlined elsewhere. 3 We rather propose an excursion into the pharmacology of kinins, the first author having been a spectator and an actor in the field for the past 35 years. There will be a strong autobiographic bias in the selection of the illustration material. We hope this partiality will be forgiven in light of the generous invitation he has received to summarize the field during an oral presentation at the 8th C1-Inhibitor Deficiency Workshop.
The Journal of Angioedemasit amet to inactivation by peptidases ( Fig. 1 ). Icatibant (Firazyr ® Shire Human Genetic Therapies, Inc, Lexington, Massachusetts, Hoe 140) 5 is an excellent prototype of the peptide B 2 R antagonists exploited in hundreds of basic science studies; it is presently approved for the management of hereditary angioedema attacks. 6 Icatibant is apparently a competitive (surmountable) antagonist at the human form of the B 2 R, but the peptide may be insurmountable and/or a partial agonist in other mammalian species. 7, 8 The des-Arg 9 form of icatibant is predominantly a B 1 R antagonist, 1 showing that the constrained peptide design is also viable at this receptor subtype; other highly specific peptide antagonists of this type include B-9958 ( Fig. 1 ). Peptidase-resistant agonists selective for either receptor type are interesting laboratory tools, and one of the selective B 2 R agonists of this category, B-9972, has distinctive effects on B 2 R cycling (see below). Another selective B 2 R agonist resistant to carboxypeptidases, labradimil (Cereport ® , formerly manufactured by Alkermes, Inc. Cambridge, MA, RMP-7; Fig. 1 ), has reached clinical development as an adjuvant to chemotherapy for brain tumors. In this case, the proinflammatory effect of BK was deliberately exploited to temporarily open the blood-brain barrier. However, a trial of labradimil as an adjuvant of carboplatin was inconclusive in children with brain tumors. 9 Current preclinical research indicates that a B 1 R agonist resistant to peptidases, Sar-Lys[D-Phe 8 ]desArg 9 -BK, has a superior potential to open the blood-brain barrier at the level of gliomas, the B 1 R being selectively expressed at lesion sites. 10 The pharmaceutical industry has developed a large number of nonpeptide antagonists for both BK receptor subtypes 11 ; let us mention only one for each. The B 2 R antagonist anatibant (LF 16-0687; Fig. 1 ) was used in a clinical trial for the prevention of brain edema after head injury (an inconclusive trial). 12 The clinical development of the brain penetrant B 1 R antagonist MK-0686 13 as an analgesic was interrupted after at least 2 trials for inflammatory pain, apparently because of lack of efficacy. 11 The anti-inflammatory effect of kinin receptor antagonists, well established in numerous preclinical studies, has not been evaluated in humans, but is of considerable potential interest. For instance, in inflammatory bowel disease, diarrheal symptoms may be driven by both BK receptor subtypes that mediate chloride and water secretion at the level of the intestinal epithelium. 14 In the course of structure-activity studies of nonpeptide B 2 R antagonists, Fujisawa scientists have discovered several nonpeptide partial agonists of this receptor. Compound 47a, illustrated in Figure 1 , is one of them; it has limited structural commonalities with anatibant and is an intriguing laboratory tool. 15 Docking models for peptide and some nonpeptide ligands have been proposed for both the B 1 and B 2 Rs. 1 They notably explain why the B 1 R excludes peptides possessing the Arg 9 residue and also some species discrepancies, for example, the fact that the presence of Lys at the position "zero" is critical for good affinity at the human form of the B 1 R. The models predict that the Cterminus of the ligands plunges into the central receptor cavity, whereas the N-terminus remains closer to the extracellular fluid. Based on these premises, Professor Lajos Gera has developed the full set of fluorescent agonists and antagonists for both the B 1 R and B 2 R by prolonging their structure at the N-terminus ( Fig. 1 ). 16 
BRADYKININ

RECPTORS: EXPRESSION AND SIGNALING
In mammalian genomes, the 2 genes encoding the BK B 2 R and B 1 R, termed BDKRB2 and BDKRB1, respectively, are located next to each other, in tandem and in this order ( Fig. 2, marker 1) . In the human chromosome 14q32 region schematically represented (about 70 kb, from position 94.66 to 94.73 Mb), the 3 major exons of each gene are shown (not precisely to scale). 1 B 2 R expression is constitutive in a large number of tissues. The B 1 R is an exceptional GPCR that is inducible, notably under the influence of tissue injury, cytokines, and the signaling systems mentioned in Figure 2 . 17, 18 The injection of bacterial lipopolysaccharide in laboratory animals, including a primate species, is a historic model to sensitize the whole cardiovascular system to B 1 R agonists, with such responses as hypotension, vasodilation, and increased vascular permeability ( Fig. 2 , marker 2). 19, 20 This can be modeled at the cellular level: for instance, the B 1 R is synergistically upregulated in human umbilical vein endothelial cells (HUVECs) by cotreatment with tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) (mRNA measurements or radioligand binding assay, Fig. 2 , marker 3, graph on right). 18 Thus, B 1 R induction is clearly regulated at the transcriptional level, with very small concentrations in healthy tissues, and extends the organism's response to a broader spectrum of kinin metabolites as a function of time and physiological state. Although the cellular concentration of the mRNA coding for B 2 R often varies in parallel with that of B 1 R in immunopathology or in response to cytokines (as in HUVECs), 18 the former receptor subtype does not seems much regulated at the level of transcription, possibly because the B 2 R protein is constitutive, recycled, and long-lived, as we will see below. Baseline populations of B 1 Rs are also observed in cultured cells that are assumed to be resting, as in radioligand binding studies applied to human vascular cells, 17, 18 for example, in HUVECs maintained in commercial endothelial cell growth medium ( Fig. 2, marker 3) . However, it seems to be an artifact linked to cell stimulation with serum, growth factors, and culture conditions. Stimulation with various cytokines (TNF-α, IFN-γ, interleukin-1, epidermal growth factor etc.) clearly upregulates the B 1 R protein and function in these models. 
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Both B 1 and B 2 Rs are mainly coupled to protein G q , itself activating a phosphoinositide phospholipase C-β that hydrolyzes phosphatidylinositol 4,5-bisphosphate present in the plasma membrane into inositol 1,4,5-trisphosphate (IP 3 ) + diacylglycerol (Fig. 2, marker 4) . The latter lipid stays in the membrane and recruits various isoforms of protein kinase C that may sequentially determine the activation of the MEK/ERK mitogen-activated protein kinases and c-Fos expression and phosphorylation. 15, 21 The phosphosugar IP 3 is the activator of the IP 3 receptor of the endoplasmic reticulum (ER) that is a high conductance ligand-gated calcium channel. Thus, stimulation of either BK receptor subtype rapidly releases ER Ca 2+ stores to raise cytosolic Ca 2+ concentrations. This was assessed by the variation of FURA-2 fluorescence read at 510 nm under excitation at 340 nm in HUVECs cultured as described 18, 22 ; cells were stimulated with BK with or without a submaximal concentration of the B 2 R antagonist anatibant (unpublished results from our laboratory, Fig. 2 , marker 3, left graph). Other mechanisms may contribute to late Ca 2+ entry from the extracellular fluid in activated vascular cells. 23 Ca 2+ activates relevant enzymatic systems in endothelial cells, either directly (cytosolic phospholipase A 2 ) or via its binding to calmodulin (endothelial nitric oxide synthase; myosin light chain kinase, MLCK). Messenger molecules produced by the endothelium, of which NO and prostaglandin I 2 are prime examples, relax the arteriolar smooth muscle cells ( Fig. 2, marker 5) , supporting the vasodilation that is the basis of specific cardinals signs of inflammation (rubor, calor). The MLCK-mediated activation of the contraction of actin-myosin cytoskeleton leads to the retraction of endothelial cells, making them leaky, particularly at the level of postcapillary venules, and to the exocytosis of Weibel-Palade bodies containing Pselectin. 24 This leads to the extravasation of fluid, proteins and, eventually, inflammatory cells that supports tumor, tissue edema. As kinins stimulate the abundant afferent nerves ending present in tissues (eg, in airway mucosae), neurogenic inflammation driven by the antidromic release of proinflammatory neuropeptides and tissue leukocytes responsive to them can amplify edema. 25 The proinflammatory effects of BK-related peptides are largely asymmetric, favoring the vascular manifestations of the process vs leukocyte recruitment; there are few credible effects of kinins on blood leukocytes. The B 1 R gene knockout mouse exhibits a minor deficit of phagocyte migration at inflammatory sites; this effect may be primarily vascular as des-Arg 9 -BK increases chemokine production in the endothelium, the likely explanation for the B 1 R-mediated facilitation of neutrophil extravasation. 26
BRADYKININ RECEPTOR ADAPTATION
The adaptation function of the agonist-stimulated B 2 R is a typical feature of GPCRs in general in the sense that it follows a sequence of events well documented for a number of other receptors 1 : a Ser/Thr rich domain of the intracellular C-terminal tail of the B 2 R sequence is phosphorylated by several GPCR kinases; the 2 nonvisual arrestins (β-arrestin 1 and 2 ) can associate with the phosphorylated receptor and compete with the G protein, thus desensitizing the receptor. Adaptor and structural proteins, which probably include AP-2 and clathrin in the case of the B 2 R, 27 direct the receptor to a pit that can leave the plasma membrane and acquire the properties of the early endosome (Fig. 3 , bottom, schematic representation). These events can be modeled using fluorescent receptors, arrestins, and ligands in HEK 293 (a) cells (Fig. 3, top) . The rabbit B 2 R fused to the green fluorescent protein (GFP) is translocated from the cell surface to multiples and polymorphic endosomes on BK stimulation; various approaches (microscopy, binding assays, immunoblots) show the complete recycling of the receptor in 1 to 3 hours. 28 The β-arrestins have a smooth cytosolic distribution in resting cells but, in cells expressing a nonfluorescent B 2 R that are further stimulated with BK, the fluorescence associated with the fusion protein β-arrestin 2 -GFP condenses in endocytic structures (Fig. 3) . 15 Other cells that express nonfluorescent B 2 Rs can be labeled with the fluorescent antagonist B-10380 or agonist CF-εACA-BK (peptide structures given in Fig. 1 , confocal imaging of HEK 293a cells in Fig. 3 ), but the subcellular distribution of the fluorescence is very different. While the antagonist labels the resting B 2 R essentially at the cell surface, the fluorescent agonist labels endosomal structures, and evidence of endosomal breakdown of the agonist is provided by the fact that some of the carboxyfluorescein label of the peptide is transferred as a function of time in the cytosol (Fig. 3 ). 29 Thus, the B 2 R transports the agonist ligands into cells and this leads to their degradation. Microscopic studies in short-term experiments (30-min incubation periods with the agonist) fully support the colocalization of the agonist-B 2 R-arrestin triad in early endosomes; Rab5 is also colocalized at this stage. Then, protein phosphatases dephosphorylate the B 2 Rs, which are ready to be recycled to the cell surface (Fig. 3, bottom) . 1 Recent evidence based on cytoskeletal-disrupting drugs and dominant negative (GDP-locked) Rab GTPases points out that the progression of the ligand-B 2 R-arrestin cargo from the cell surface to the perinuclear space is dependent on Rab5-mediated displacement of early endosomes along tubulin fibers and that the recycling process is entirely different, dependent on Rab4 and Rab11 and the actin cytoskeleton. 30 The intraendosomal inactivation of BK is also critical for the time course of B 2 R recycling as shown by an inactivation-resistant peptide agonist, B-9972, or by a nonpeptide partial agonist, The Journal of Angioedemasit amet compound 47a (structures in Fig. 1 ). 15, 31 An amphibian BK homologue termed maximakinin also acts as an inactivation-resistant agonist. 32 In all these cases, no or little B 2 R recycling is observed in the 12-hour incubation period following cell stimulation, and a sizeable proportion of the receptor is destroyed (immunoblot evidence), presumably after progression into the late endosomelysosome continuum.
The B 1 R has an intracellular C-terminal tail that is not well conserved in sequence between mammalian species and that is very short in some mammalian species. 1 Accordingly, the B 1 R is not phosphorylated on agonist stimulation 33 and does not promote condensation of the cytosolic β-arrestins at endosomal or plasma membrane levels ( Fig. 3 top, unpublished results) . Thus B 1 Rs lack a basic desensitization mechanism of the B 2 R and may signal for prolonged periods in some systems. 1 However, an unexpected discovery based on a fusion protein of the rabbit B 1 R with the yellow fluorescent protein (YFP) was the lateral agonist-induced translocation of the B 1 R into structures that remain close to the plasma membrane plane (confocal microscopy, Fig. 3, top) . 34 These structures are disrupted by cholesterol extraction from the cells and are likely to be caveolae, the lipid rafts that can be resolved in optical microscopy. This view is supported by the labeling of nonfluorescent rabbit or human B 1 Rs by fluorescent ligands (Fig. 3, top ; the human B 1 Rs are illustrated using confocal microscopy). While the antagonist B-10376 essentially labels resting B 1 Rs in the plasma membrane in a continuous manner, the agonist B-10378 has no significant endosomal distribution, but a rather spotty plasma membrane location ( Fig. 3, top ; peptide structures in Fig. 1 ). 35 Microscopic studies support that caveolin-1 is colocalized with B-10378 33 and with agonist-stimulated B 1 R-YFP. 34 In addition, cell fractionation studies that aimed to recover The Journal of Angioedemasit amet buoyant caveolae-related lipid rafts from cells prelabeled with either an agonist or an antagonist radioligand showed that the agonist version is highly enriched in such rafts, as opposed to the antagonist. This applied both to HEK 293 cells overexpressing B 1 R-YFP 33 or to cultured human vascular smooth muscle cells expressing endogenous B 1 Rs (see supplemental material). Caveolae, particularly prominent in vascular endothelial cells, are signaling platforms of interest where the protein G αq , a signaling partner of the B 1 R, is enriched.
Another noticeable difference of interest between the 2 BK receptor subtypes is their apparent half-life as mature proteins at the cell surface. The discussion above about the B 2 R cycling makes clear that it is economically managed and it is also long-lived. 36 Like other gene products induced during inflammatory conditions (eg, inducible nitric oxide synthase), the B 1 R is short-lived (t 1/2 2-4 h), being eliminated from the cell surface in a ligandindependent manner (schematic representation, Fig. 3 
